Fenchol FFAR2 Activation for Amyloid-Beta Clearance in Alzheimer's

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Current therapies for Alzheimer's disease (AD) are ineffective in reducing amyloid-beta (Aβ) accumulation, leading to neurodegeneration and cognitive decline, and strategies to modulate gut microbiota for AD pathology are largely unknown.

Innovation Solution

Administering fenchol, a natural compound that activates Free Fatty Acid Receptor 2 (FFAR2) signaling, to increase Aβ clearance through enhanced proteasome and lysosomal activities, thereby reducing Aβ accumulation and ameliorating AD-like pathology.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If current therapies are used to treat Alzheimer's disease, then patients receive standard treatment, but Aβ accumulation is not reduced and neurodegeneration continues

Engineering Contradiction:

Improveeffectiveness of AD treatmentVSAvoidAβ accumulation and neurotoxicity

Core Design Contradiction:

ReliabilityVSObject-affected harmful factors

Solution Approach 1:

The invention changes the biochemical parameters of the system by introducing fenchol, which activates FFAR2 signaling and alters proteasome and lysosomal activities. This leads to changed clearance rates of Aβ, transitioning the system from a state of accumulation to a state of reduced accumulation and improved clearance.

Inventive Principle:

Principle #35Parameter changes

Solution Approach 2:

Fenchol acts as an intermediary substance that mediates between the existing therapeutic approaches and the desired outcome of reduced Aβ accumulation. It activates FFAR2 receptors as an intermediate step, which then triggers downstream effects on proteasome and lysosomal functions, ultimately reducing Aβ levels without directly targeting Aβ itself.

Inventive Principle:

Principle #24Intermediary (Mediator)

2Productivity

If Aβ clearance is increased through proteasome and lysosomal activation, then Aβ accumulation is reduced, but the mechanism requires novel therapeutic compounds like fenchol

Engineering Contradiction:

ImproveAβ clearance rateVSAvoidtherapeutic mechanism complexity

Core Design Contradiction:

ProductivityVSDevice complexity

Solution Approach 1:

The invention enables the cell's own proteasome and lysosomal systems to perform the service of Aβ clearance more effectively. By activating FFAR2 signaling, fenchol stimulates the cell's intrinsic degradation machinery to work harder and more efficiently at clearing Aβ, rather than requiring external direct intervention on Aβ itself.

Inventive Principle:

Principle #25Self-service

Solution Approach 2:

The invention performs preliminary action by activating FFAR2 signaling pathways before Aβ accumulation becomes problematic. By upregulating proteasome and lysosomal activities in advance, the system is prepared to handle Aβ clearance more effectively, preventing accumulation rather than just responding to it.

Inventive Principle:

Principle #10Preliminary action

3Reliability

If fenchol is administered to activate FFAR2 signaling, then Aβ clearance is enhanced and neurotoxicity is reduced, but the compound must be delivered effectively to the brain

Engineering Contradiction:

Improveneuroprotective effectVSAvoiddrug delivery to brain

Core Design Contradiction:

ReliabilityVSEase of operation

Solution Approach 1:

Fenchol demonstrates multi-functionality by simultaneously activating FFAR2 receptors, enhancing proteasome activity, boosting lysosomal function, and reducing neurotoxicity. This single compound performs multiple therapeutic functions that would otherwise require a complex combination of different drugs, simplifying the treatment regimen while achieving comprehensive neuroprotection.

Inventive Principle:

Principle #6Universality (Multi-functionality)

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

Fenchol treatment significantly reduces Aβ-induced neurotoxicity, enhances neuronal cell viability, and improves cognitive functions by increasing Aβ clearance and proteasome activity, providing a potential therapeutic approach for AD.

Implementation Method 1

fenchol, a natural compound that activates Free Fatty Acid Receptor 2 (FFAR2) signaling

Methodology Applied

Scientific EffectReceptor activation signaling:

Implementation Method 2

increase Aβ clearance through enhanced proteasome and lysosomal activities

Methodology Applied

Scientific EffectProteasome activity enhancement:

Implementation Method 3

increase Aβ clearance through enhanced proteasome and lysosomal activities

Methodology Applied

Scientific EffectLysosomal degradation:

Data Source

PatentUS20260014098A1Fenchol as a stimulator of free fatty acid receptor and other uses thereof

Publication Date: 2026.01.15 UNIV OF SOUTH FLORIDA

AI summary

Described are methods of treating neurodegenerative disease by administering a therapeutically effective amount of fenchol to a patient in need thereof. Additionally, described are methods of activating FFAR2 signaling in a patient by administering a therapeutically effective amount of fenchol to a patient in need thereof. Methods of treating gastrointestinal disorders in a patient being treated for cancer and methods of improving cognition in a patient being treated for cancer are also described. Further, the present disclosure provides for a pharmaceutical composition including fenchol and an Alzheimer's disease drug. Additionally, a nasal spray including fenchol, a buccal tablet including fenchol, and a dietary supplement including fenchol are described.